Treatment success rate: XDR-TB cases in Eastern Mediterranean (WHO region)
Eastern Mediterranean (WHO region): Treatment success rate: XDR-TB cases was 74 in 2022. ▲ Rising
Treatment success rate: XDR-TB cases in Eastern Mediterranean (WHO region), 2008–2022
Source: World Health Organization, Global Health Observatory.
Analysis
In 2022, treatment success rate: xdr-tb cases in Eastern Mediterranean (WHO region) stood at 74. That is the highest value across all 15 years on record.
Compared with earlier readings it is up 4.2% on the previous year and up 124.2% over ten years.
Over the whole period, treatment success rate: xdr-tb cases in Eastern Mediterranean (WHO region) peaked at 74 in 2022 and was at its lowest, 0, in 2008.
The long-run direction has been consistently rising across the 15 years of available data.
Treatment success rate: XDR-TB cases in Eastern Mediterranean (WHO region), year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0 | — |
| 2009 | 50 | — |
| 2010 | 45 | -10.0% |
| 2011 | 38 | -15.6% |
| 2012 | 33 | -13.2% |
| 2013 | 30 | -9.1% |
| 2014 | 42 | +40.0% |
| 2015 | 29 | -31.0% |
| 2016 | 37 | +27.6% |
| 2017 | 44 | +18.9% |
| 2018 | 49 | +11.4% |
| 2019 | 65 | +32.7% |
| 2020 | 71 | +9.2% |
| 2021 | 71 | +0.0% |
| 2022 | 74 | +4.2% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 25 | 0 | 50 | 2 |
| 2010s | 41.2 | 29 | 65 | 10 |
| 2020s | 72 | 71 | 74 | 3 |
Countries ranked near Eastern Mediterranean (WHO region)
- 1 Australia 100 compare
- 1 Nicaragua 100 compare
- 1 United States of America 100 compare
- 1 Equatorial Guinea 100 compare
- 1 Tanzania, United Republic of 100 compare
- 1 Morocco 100 compare
- 1 Hong Kong, China 100 compare
- 1 Papua New Guinea 100 compare
- 1 Niger 100 compare
- 1 Portugal 100 compare
- 1 Israel 100 compare
- 1 Botswana 100 compare
- 1 Congo, Democratic Republic of the 100 compare
- 1 Cameroon 100 compare
- 1 Panama 100 compare
- 1 Somalia 100 compare
- 1 Canada 100 compare
More health data for Eastern Mediterranean (WHO region)
- Measles - number of reported cases, gaps filled 83,590 (2025)
- Diphtheria - number of reported cases, gaps filled 5,830 (2025)
- Total tetanus - number of reported cases, gaps filled 524 (2025)
- Pertussis - number of reported cases, gaps filled 14,992 (2025)
- Measles - number of reported cases, annual growth rate 6.13 % change on previous year (2025)
- Pertussis - number of reported cases, annual growth rate 140.84 % change on previous year (2025)
- Total tetanus - number of reported cases, annual growth rate 11.73 % change on previous year (2025)
- Diphtheria - number of reported cases 5,830 (2025)
- Measles - number of reported cases 83,590 (2025)
- Total tetanus - number of reported cases 524 (2025)
Frequently asked questions
- What is treatment success rate: xdr-tb cases in Eastern Mediterranean (WHO region)?
- Treatment success rate: xdr-tb cases in Eastern Mediterranean (WHO region) was 74 in 2022, according to World Health Organization, Global Health Observatory.
- What is the highest treatment success rate: xdr-tb cases recorded in Eastern Mediterranean (WHO region)?
- The highest recorded value was 74 in 2022.
- What is the lowest treatment success rate: xdr-tb cases recorded in Eastern Mediterranean (WHO region)?
- The lowest recorded value was 0 in 2008.
- How does Eastern Mediterranean (WHO region) rank for treatment success rate: xdr-tb cases?
- Eastern Mediterranean (WHO region) ranks 1st out of 11 groups with data for 2022.
- Is treatment success rate: xdr-tb cases rising or falling in Eastern Mediterranean (WHO region)?
- Over the last ten years it is up 124.2%. The long-run trend across the full record is rising.
- Where does this Eastern Mediterranean (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Treatment success rate: XDR-TB cases. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 15 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).